
LFCR Stock Forecast & Price Target
LFCR Analyst Ratings
Bulls say
Lifecore Biomedical has experienced growth in its HA manufacturing segment, predominantly due to favorable order timing from its largest customer, resulting in a 9.8% increase in revenue in the latest quarter compared to the previous year. The company projects a significant increase in developmental revenue over the next few years, targeting 60% capacity utilization by 2029, which suggests a robust growth trajectory from its current 20% utilization level in 2025. Additionally, Lifecore has successfully secured three commercial site transfer programs in the last five months, indicating its increasing appeal as a manufacturing partner and reinforcing expectations of operational momentum that could contribute to a projected revenue CAGR of 12% by 2029.
Bears say
Lifecore Biomedical has experienced a significant drop in share price, declining over 50% in the past two months, primarily attributed to disappointing fiscal year 2026 guidance and conservative expectations for fiscal year 2027 growth. The company's revenue challenges stem from a notable decline in contract development and manufacturing (CDMO) revenue, influenced by a key customer loss, inventory rebalancing by a major client, and delayed product launches related to customer funding issues. While there was modest growth in hyaluronic acid (HA) manufacturing revenue, the overall financial outlook remains clouded by concerns over future capital needs and the potential for additional revenue headwinds.
This aggregate rating is based on analysts' research of Lifecore Biomedical Inc and is not a guaranteed prediction by Public.com or investment advice.
LFCR Analyst Forecast & Price Prediction
Start investing in LFCR
Order type
Buy in
Order amount
Est. shares
0 shares